Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics

International Journal of Molecular Sciences

Volumn 15, Issue 5, 2014, Pages 7865-7882

  Liu, Yahui ^a   Qing, Hong ^a   Deng, Yulin ^a  

^a BEIJING INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Alzheimer's disease; Biomarker; Mass spectrometry; Proteomics

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; PLASMA PROTEIN; PROTEIN; PROTEIN CEREBROSPINAL FLUID LEVEL;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; DEMENTIA; DNA METHYLATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PEPTIDOMICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN MICROARRAY; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; WESTERN BLOTTING; ANALYSIS; ANIMAL; BLOOD; PROCEDURES; PROTEIN CEREBROSPINAL FLUID LEVEL;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; BLOOD PROTEINS; CEREBROSPINAL FLUID PROTEINS; HUMANS; MASS SPECTROMETRY; PROTEINS; PROTEOMICS;

EID: 84899978366     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15057865     Document Type: Review

References (133)

1. Zhang, X.; Li, L.; Wei, D.; Yap, Y.; Chen, F. Moving cancer diagnostics from bench to bedside. Trends Biotechnol. 2007, 25, 166-173.
2. Rifai, N.; Gillette, M.A.; Carr, S.A. Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
3. Poste, G. Bring on the biomarkers. Nature 2011, 469, 156-157.
4. Puntmann, V.O. How to guide on biomarkers: Biomarker definitions, Validation and applications with examples from cardiovascular disease. Postgrad. Med. J. 2009, 85, 538-545.
5. Anderson, D.C.; Kodukula, K. Biomarkers in pharmacology and drug discovery. Biochem. Pharmacol. 2014, 87, 172-188.
6. Ballard, C.; Gauthier, S.; Corbett, A.; Brayne, C.; Aarsland, D.; Jones, E. Alzheimer's disease. Lancet 2011, 377, 1019-1031.
7. Ghidoni, R.; Paterlini, A.; Benussi, L. Translational proteomics in Alzheimer's disease and related disorders. Clin. Biochem. 2013, 46, 480-486.
8. Podlesniy, P.; Figueiro-Silva, J.; Llado, A.; Antonell, A.; Sanchez-Valle, R.; Alcolea, D.; Lleo, A.; Molinuevo, J.L.; Serra, N.; Trullas, R. Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical alzheimer disease. Ann. Neurol. 2013, 74, 655-668.
9. Blennow, K.; Hampel, H.; Weiner, M.; Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in alzheimer disease. Nat. Rev. Neurol. 2010, 6, 131-144.
10. Hampel, H.; Blennow, K.; Shaw, L.M.; Hoessler, Y.C.; Zetterberg, H.; Trojanowski, J.Q. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp. Gerontol. 2010, 45, 30-40.
11. Trojanowski, J.Q.; Vandeerstichele, H.; Korecka, M.; Clark, C.M.; Aisen, P.S.; Petersen, R.C.; Blennow, K.; Soares, H.; Simon, A.; Lewczuk, P.; et al. Update on the biomarker core of the Alzheimer's disease neuroimaging initiative subjects. Alzheimer's Dement. 2010, 6, 230-238.
12. Weiner, M.W.; Veitch, D.P.; Aisen, P.S.; Beckett, L.A.; Cairns, N.J.; Green, R.C.; Harvey, D.; Jack, C.R.; Jagust, W.; Liu, E.; et al. The Alzheimer's disease neuroimaging initiative: A review of papers published since its inception. Alzheimer's Dement. 2012, 8, S1-S68.
13. Whiteaker, J.R.; Lin, C.; Kennedy, J.; Hou, L.; Trute, M.; Sokal, I.; Yan, P.; Schoenherr, R.M.; Zhao, L.; Voytovich, U.J.; et al. A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat. Biotechnol. 2011, 29, 625-634.
14. Anderson, N.L. The clinical plasma proteome: A survey of clinical assays for proteins in plasma and serum. Clin. Chem. 2010, 56, 177-185.
15. Nature editorial office. Valid concerns. The reporting of candidate biomarkers for disease must be rigorous to drive translational research. Nature 2010, 463, 401-402.
16. Prvulovic, D.; Hampel, H. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Clin. Chem. Lab. Med. 2011, 49, 367-374.
17. Watt, A.D.; Perez, K.A.; Faux, N.G.; Pike, K.E.; Rowe, C.C.; Bourgeat, P.; Salvado, O.; Masters, C.L.; Villemagne, V.L.; Barnham, K.J. Increasing the predictive accuracy of amyloid-beta blood-borne biomarkers in Alzheimer's disease. J. Alzheimer's Dis. 2011, 24, 47-59.
18. Rosenmann, H. CSF biomarkers for amyloid and tau pathology in Alzheimer's disease. J. Mol. Neurosci. 2012, 47, 1-14.
19. Zhang, Y.; Fonslow, B.R.; Shan, B.; Baek, M.C.; Yates, J.R., Protein analysis by shotgun/bottom-up proteomics. Chem. Rev. 2013, 113, 2343-2394.
20. Ramaswamy, S.; Perou, C.M. DNA microarrays in breast cancer: The promise of personalised medicine. Lancet 2003, 361, 1576-1577.
21. Simpson, R.J.; Lim, J.W.; Moritz, R.L.; Mathivanan, S. Exosomes: Proteomic insights and diagnostic potential. Expert Rev. Proteomics 2009, 6, 267-283.
22. Kit, H.A.; Nielsen, H.M.; Tost, J. DNA methylation based biomarkers: Practical considerations and applications. Biochimie 2012, 94, 2314-2337.
23. Thambisetty, M.; Lovestone, S. Blood-based biomarkers of Alzheimer's disease: Challenging but feasible. Biomark. Med. 2010, 4, 65-79.
24. Hunter, M.P.; Ismail, N.; Zhang, X.; Aguda, B.D.; Lee, E.J.; Yu, L.; Xiao, T.; Schafer, J.; Lee, M.L.; Schmittgen T.D.; et al. Detection of microrna expression in human peripheral blood microvesicles. PLoS One 2008, 3, doi:10.1371/journal.pone.0003694.
25. Muller, M.; Kuiperij, H.B.; Claassen, J.A.; Kusters, B.; Verbeek, M.M. MicroRNAs in Alzheimer's disease: Differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol. Aging 2014, 35, 152-158.
26. Lukiw, W.J. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 2007, 18, 297-300.
27. Wang, X.; Liu, P.; Zhu, H.; Xu, Y.; Ma, C.; Dai, X.; Huang, L.; Liu, Y.; Zhang, L.; Qin, C. MiR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res. Bull. 2009, 80, 268-273.
28. Lukiw, W.J.; Alexandrov, P.N.; Zhao, Y.; Hill, J.M.; Bhattacharjee, S. Spreading of Alzheimer's disease inflammatory signaling through soluble micro-RNA. Neuroreport 2012, 23, 621-626.
29. Alexandrov, P.N.; Dua, P.; Hill, J.M.; Bhattacharjee, S.; Zhao, Y.; Lukiw, W.J. MicroRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int. J. Biochem. Mol. Biol. 2012, 3, 365-373.
30. Wang, W.X.; Rajeev, B.W.; Stromberg, A.J.; Ren, N.; Tang, G.; Huang, Q.; Rigoutsos, I.; Nelson, P.T. The expression of microRNA MIR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of β-site amyloid precursor protein-cleaving enzyme 1. J. Neurosci. 2008, 28, 1213-1223.
31. Geekiyanage, H.; Jicha, G.A.; Nelson, P.T.; Chan, C. Blood serum miRNA: Non-invasive biomarkers for Alzheimer's disease. Exp. Neurol. 2012, 235, 491-496.
32. Liu, W.; Liu, C.; Zhu, J.; Shu, P.; Yin, B.; Gong, Y.; Qiang, B.; Yuan, J.; Peng, X. MicroRNA-16 targets amyloid precursor protein to potentially modulate alzheimer's-associated pathogenesis in samp8 mice. Neurobiol. Aging 2012, 33, 522-534.
33. Cogswell, J.P.; Ward, J.; Taylor, I.A.; Waters, M.; Shi, Y.; Cannon, B.; Kelnar, K.; Kemppainen, J.; Brown, D.; Chen, C.; et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J. Alzheimer's Dis. 2008, 14, 27-41.
34. Schonrock, N.; Matamales, M.; Ittner, L.M.; Gotz, J. MicroRNA networks surrounding APP and amyloid-β metabolism-implications for Alzheimer's disease. Exp. Neurol. 2012, 235, 447-454.
35. Tan, L.; Yu, J.T.; Hu, N. Non-coding RNAs in Alzheimer's disease. Mol. Neurobiol. 2013, 47, 382-393.
36. Sheinerman, K.S.; Tsivinsky, V.G.; Abdullah, L.; Crawford, F.; Umansky, S.R. Plasma microRNA biomarkers for detection of mild cognitive impairment: Biomarker validation study. Aging 2013, 5, 925-938.
37. Sheinerman, K.S.; Tsivinsky, V.G.; Crawford, F.; Mullan, M.J.; Abdullah, L.; Umansky, S.R. Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging 2012, 4, 590-605.
38. Kiko, T.; Nakagawa, K.; Tsuduki, T.; Furukawa, K.; Arai, H.; Miyazawa, T. MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer's disease. J. Alzheimer's Dis. 2014, 39, 253-259.
39. Thadikkaran, L.; Siegenthaler, M.A.; Crettaz, D.; Queloz, P.A.; Schneider, P.; Tissot, J.D. Recent advances in blood-related proteomics. Proteomics 2005, 5, 3019-3034.
40. Zürbig, P.; Jahn, H. Use of proteomic methods in the analysis of human body fluids in Alzheimer research. Electrophoresis 2012, 33, 3617-3630.
41. Mayeux, R.; Schupf, N. Blood-based biomarkers for Alzheimer's disease: Plasma Aβ40 and Aβ42, and genetic variants. Neurobiol. Aging 2011, 32, S10-S19.
42. Issaq, H.J.; Xiao, Z.; Veenstra, T.D. Serum and plasma proteomics. Chem. Rev. 2007, 107, 3601-3620.
43. Koyama, A.; Okereke, O.I.; Yang, T.; Blacker, D.; Selkoe, D.J.; Grodstein, F. Plasma amyloid-β as a predictor of dementia and cognitive decline: A systematic review and meta-analysis. Arch. Neurol. 2012, 69, 824-831.
44. Gupta, V.B.; Laws, S.M.; Villemagne, V.L.; Ames, D.; Bush, A.I.; Ellis, K.A.; Lui, J.K.; Masters, C.; Rowe, C.C.; Szoeke, C.; et al. Plasma apolipoprotein E and alzheimer disease risk. Neurology 2011, 76, 1091-1098.
45. Yang, M.H.; Yang, Y.H.; Lu, C.Y.; Jong, S.B.; Chen, L.J.; Lin, Y.F.; Wu, S.J.; Chu, P.Y.; Chung, T.W.; Tyan, Y.C. Activity-dependent neuroprotector homeobox protein: A candidate protein identified in serum as diagnostic biomarker for Alzheimer's disease. J. Proteomics 2012, 75, 3617-3629.
46. Du, Y.; Dodel, R.C.; Eastwood, B.J.; Bales, K.R.; Gao, F.; Lohmuller, F.; Muller, U.; Kurz, A.; Zimmer, R.; Evans, R.M.; et al. Association of an interleukin 1α polymorphism with Alzheimer's disease. Neurology 2000, 55, 480-483.
47. Adams, S.; Harold, A.; Bremner, W.; Bhatti, A. Immediate post-parathyroidectomy stridor resolved with intravenous calcium. BMJ Case Rep. 2009, 2009, doi:10.1136/bcr.09.2008.0938.
48. Lambert, J.C.; Heath, S.; Even, G.; Campion, D.; Sleegers, K.; Hiltunen, M.; Combarros, O.; Zelenika, D.; Bullido, M.J.; Tavernier, B.; et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41, 1094-1099.
49. Oishi, M.; Mochizuki, Y.; Yoshihashi, H.; Takasu, T.; Nakano, E. Laboratory examinations correlated with severity of dementia. Ann. Clin. Lab. Sci. 1996, 26, 340-345.
50. Karsidag, T.; Tuzun, S.; Kemik, A.S.; Purisa, S.; Unlu, A. Alpha-1 protease inhibitor and antichymotrypsin levels in acute pancreatitis. Turkish J. Trauma Emerg. Surg. 2012, 18, 195-199.
51. Guan, F.; Gu, J.; Hu, F.; Zhu, Y.; Wang, W. Association between α1-antichymotrypsin signal peptide-15A/T polymorphism and the risk of Alzheimer's disease: A meta-analysis. Mol. Biol. Rep. 2012, 39, 6661-6669.
52. Zamostiano, R.; Pinhasov, A.; Gelber, E.; Steingart, R.A.; Seroussi, E.; Giladi, E.; Bassan, M.; Wollman, Y.; Eyre, H.J.; Mulley, J.C.; et al. Cloning and characterization of the human activity-dependent neuroprotective protein. J. Biol. Chem. 2001, 276, 708-714.
53. Fernandez-Montesinos, R.; Torres, M.; Baglietto-Vargas, D.; Gutierrez, A.; Gozes, I.; Vitorica, J.; Pozo, D. Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. J. Mol. Neurosci. 2010, 41, 114-120.
54. Shaw, L.M.; Korecka, M.; Clark, C.M.; Lee, V.M.; Trojanowski, J.Q. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat. Rev. Drug Discov. 2007, 6, 295-303.
55. Sonnen, J.A.; Keene, C.D.; Montine, K.S.; Li, G.; Peskind, E.R.; Zhang, J.; Montine, T.J. Biomarkers for Alzheimer's disease. Expert Rev. Neurother. 2007, 7, 1021-1028.
56. Clark, C.M.; Davatzikos, C.; Borthakur, A.; Newberg, A.; Leight, S.; Lee, V.M.; Trojanowski, J.Q. Biomarkers for early detection of Alzheimer pathology. Neurosignals 2008, 16, 11-18.
57. De Almeida, S.M.; Shumaker, S.D.; LeBlanc, S.K.; Delaney, P.; Marquie-Beck, J.; Ueland, S.; Alexander, T.; Ellis, R.J. Incidence of post-dural puncture headache in research volunteers. Headache 2011, 51, 1503-1510.
58. Oreskovic, D.; Klarica, M., The formation of cerebrospinal fluid: Nearly a hundred years of interpretations and misinterpretations. Brain Res. Rev. 2010, 64, 241-262.
59. Kroksveen, A.C.; Opsahl, J.A.; Aye, T.T.; Ulvik, R.J.; Berven, F.S. Proteomics of human cerebrospinal fluid: Discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J. Proteomics 2011, 74, 371-388.
60. Miller, L.L.; Bale, W.F. Synthesis of all plasma protein fractions except gamma globulins by the liver; The use of zone electrophoresis and lysine-epsilon-C14 to define the plasma proteins synthesized by the isolated perfused liver. J. Exp. Med. 1954, 99, 125-132.
61. Blennow, K.; Wallin, A.; Fredman, P.; Karlsson, I.; Gottfries, C.G.; Svennerholm, L. Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol. Scand. 1990, 81, 323-326.
62. 2+-Dependent phospholipase A2 activity is increased in alzheimer disease. Clin. Chem. 2009, 55, 2171-2179.
63. 2+-dependent phospholipase A2 activity: A biomarker of blood-cerebrospinal fluid barrier permeability. Neurosci. Lett. 2010, 478, 179-183.
64. Laterza, O.F.; Modur, V.R.; Crimmins, D.L.; Olander, J.V.; Landt, Y.; Lee, J.M.; Ladenson, J.H. Identification of novel brain biomarkers. Clin. Chem. 2006, 52, 1713-1721.
65. Lee, J.M.; Blennow, K.; Andreasen, N.; Laterza, O.; Modur, V.; Olander, J.; Gao, F.; Ohlendorf, M.; Ladenson, J.H. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin. Chem. 2008, 54, 1617-1623.
66. Weingarten, M.D.; Lockwood, A.H.; Hwo, S.Y.; Kirschner, M.W. A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. USA 1975, 72, 1858-1862.
67. Blennow, K.; Zetterberg, H. Cerebrospinal fluid biomarkers for Alzheimer's disease. J. Alzheimer's Dis. 2009, 18, 413-417.
68. Blom, E.S.; Giedraitis, V.; Zetterberg, H.; Fukumoto, H.; Blennow, K.; Hyman, B.T.; Irizarry, M.C.; Wahlund, L.O.; Lannfelt, L.; Ingelsson, M. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement. Geriatr. Cogn. Disord. 2009, 27, 458-464.
69. Samgard, K.; Zetterberg, H.; Blennow, K.; Hansson, O.; Minthon, L.; Londos, E. Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int. J. Geriatr. Psychiatry 2010, 25, 403-410.
70. Wallin, A.K.; Hansson, O.; Blennow, K.; Londos, E.; Minthon, L. Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease? Int. J. Geriatr. Psychiatry 2009, 24, 638-647.
71. Liu, Q.; Xie, F.; Siedlak, S.L.; Nunomura, A.; Honda, K.; Moreira, P.I.; Zhua, X.; Smith, M.A.; Perry, G. Neurofilament proteins in neurodegenerative diseases. Cell Mol. Life Sci. 2004, 61, 3057-3075.
72. Brettschneider, J.; Petzold, A.; Schottle, D.; Claus, A.; Riepe, M.; Tumani, H. The neurofilament heavy chain (NFH) in the cerebrospinal fluid diagnosis of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2006, 21, 291-295.
73. Cheon, M.S.; Kim, S.H.; Fountoulakis, M.; Lubec, G. Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer's disease. J. Neural. Transm. Suppl. 2003, 225-234.
74. Perrin, R.J.; Craig-Schapiro, R.; Malone, J.P.; Shah, A.R.; Gilmore, P.; Davis, A.E.; Roe, C.M.; Peskind, E.R.; Li, G.; Galasko, D.R.; et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 2011, 6, doi:10.1371/journal.pone.0016032.
75. Mattsson, N.; Savman, K.; Osterlundh, G.; Blennow, K.; Zetterberg, H. Converging molecular pathways in human neural development and degeneration. Neurosci. Res. 2010, 66, 330-332.
76. Davidsson, P.; Blennow, K. Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int. Psychogeriatr. 1998, 10, 11-23.
77. Thorsell, A.; Bjerke, M.; Gobom, J.; Brunhage, E.; Vanmechelen, E.; Andreasen, N.; Hansson, O.; Minthon, L.; Zetterberg, H.; Blennow, K. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res. 2010, 1362, 13-22.
78. Herrmann, M.; Ebert, A.D.; Galazky, I.; Wunderlich, M.T.; Kunz, W.S.; Huth, C. Neurobehavioral outcome prediction after cardiac surgery: Role of neurobiochemical markers of damage to neuronal and glial brain tissue. Stroke 2000, 31, 645-650.
79. Peskind, E.R.; Griffin, W.S.; Akama, K.T.; Raskind, M.A.; van Eldik, L.J. Cerebrospinal fluid S-100B is elevated in the earlier stages of Alzheimer's disease. Neurochem. Int. 2001, 39, 409-413.
80. Jesse, S.; Steinacker, P.; Cepek, L.; von Arnim, C.A.; Tumani, H.; Lehnert, S.; Kretzschmar, H.A.; Baier, M.; Otto, M. Glial fibrillary acidic protein and protein S-100B: Different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease. J. Alzheimer's Dis. 2009, 17, 541-551.
81. Wang, H.; Li, R.; Shen, Y., Beta-secretase: Its biology as a therapeutic target in diseases. Trends Pharmacol. Sci. 2013, 34, 215-225.
82. Snyder, H.M.; Carrillo, M.C.; Grodstein, F.; Henriksen, K.; Jeromin, A.; Lovestone, S.; Mielke, M.M.; O'Bryant, S.; Sarasa, M.; Sjogren, M.; et al. Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimer's Dement. 2014, 10, 109-114.
83. Hilpert, H.; Guba, W.; Woltering, T.J.; Wostl, W.; Pinard, E.; Mauser, H.; Mayweg, A.V.; Rogers-Evans, M.; Humm, R.; Krummenacher, D., et al. βsecretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease. J. Med. Chem. 2013, 56, 3980-3995.
84. Altelaar, A.F.; Munoz, J.; Heck, A.J. Next-generation proteomics: Towards an integrative view of proteome dynamics. Nat. Rev. Genet. 2013, 14, 35-48.
85. Chevallet, M.; Luche, S.; Diemer, H.; Strub, J.M.; van Dorsselaer, A.; Rabilloud, T. Sweet silver: A formaldehyde-free silver staining using aldoses as developing agents, with enhanced compatibility with mass spectrometry. Proteomics 2008, 8, 4853-4861.
86. Fey, S.J.; Larsen, P.M. 2D or not 2D. Two-dimensional gel electrophoresis. Curr. Opin. Chem. Biol. 2001, 5, 26-33.
87. Song, F.; Poljak, A.; Smythe, G.A.; Sachdev, P. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res. Rev. 2009, 61, 69-80.
88. Apweiler, R.; Aslanidis, C.; Deufel, T.; Gerstner, A.; Hansen, J.; Hochstrasser, D.; Kellner, R.; Kubicek, M.; Lottspeich, F.; Maser, E., et al. Approaching clinical proteomics: Current state and future fields of application in fluid proteomics. Clin. Chem. Lab. Med. 2009, 47, 724-744.
89. Hye, A.; Lynham, S.; Thambisetty, M.; Causevic, M.; Campbell, J.; Byers, H.L.; Hooper, C.; Rijsdijk, F.; Tabrizi, S.J.; Banner, S., et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006, 129, 3042-3050.
90. Zhang, R.; Barker, L.; Pinchev, D.; Marshall, J.; Rasamoelisolo, M.; Smith, C.; Kupchak, P.; Kireeva, I.; Ingratta, L.; Jackowski, G. Mining biomarkers in human sera using proteomic tools. Proteomics 2004, 4, 244-256.
91. Thambisetty, M.; Hye, A.; Foy, C.; Daly, E.; Glover, A.; Cooper, A.; Simmons, A.; Murphy, D.; Lovestone, S. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J. Neurol. 2008, 255, 1712-1720.
92. Thambisetty, M.; Simmons, A.; Hye, A.; Campbell, J.; Westman, E.; Zhang, Y.; Wahlund, L.O.; Kinsey, A.; Causevic, M.; Killick, R., et al. Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One 2011, 6, doi:10.1371/journal.pone.0028527.
93. Thambisetty, M.; An, Y.; Kinsey, A.; Koka, D.; Saleem, M.; Guntert, A.; Kraut, M.; Ferrucci, L.; Davatzikos, C.; Lovestone, S., et al. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage 2012, 59, 212-217.
94. Henkel, A.W.; Muller, K.; Lewczuk, P.; Muller, T.; Marcus, K.; Kornhuber, J.; Wiltfang, J. Multidimensional plasma protein separation technique for identification of potential Alzheimer's disease plasma biomarkers: A pilot study. J. Neural Transm. 2012, 11 9, 779-788.
95. Buts, K.; Michielssens, S.; Hertog, M.L.; Hayakawa, E.; Cordewener, J.; America, A.H.; Nicolai, B.M.; Carpentier, S.C. Improving the identification rate of data independent label-free quantitative proteomics experiments on non-model crops: A case study on apple fruit. J. Proteomics 2014, doi:10.1016/j.jprot.2014.02.015.
96. Cole, L.M.; Bluff, J.E.; Carolan, V.A.; Paley, M.N.; Tozer, G.M.; Clench, M.R. MALDI-MSI and label free LC-ESI-MS/MS shotgun proteomics to investigate protein induction in a murine fibrosarcoma model following treatment with a vascular disrupting agent. Proteomics 2014, 14, 890-903
97. Mohayeji, M.; Capriotti, A.L.; Cavaliere, C.; Piovesana, S.; Samperi, R.; Stampachiacchiere, S.; Toorchi, M.; Lagana, A. Heterosis profile of sunflower leaves: A label free proteomics approach. J. Proteomics 2014, 99, 101-110.
98. Hakimi, A.; Auluck, J.; Jones, G.D.; Ng, L.L.; Jones, D.J. Assessment of reproducibility in depletion and enrichment workflows for plasma proteomics using label-free quantitative data-independent LC-MS. Proteomics 2014, 14, 4-13.
99. Liu, X.; Hu, Y.; Pai, P.J.; Chen, D.; Lam, H. Label-free quantitative proteomics analysis of antibiotic response in staphylococcus aureus to oxacillin. J. Proteome Res. 2014, 13, 1223-1233.
100. Zhang, J.; Goodlett, D.R.; Quinn, J.F.; Peskind, E.; Kaye, J.A.; Zhou, Y.; Pan, C.; Yi, E.; Eng, J.; Wang, Q.; et al. Quantitative proteomics of cerebrospinal fluid from patients with alzheimer disease. J. Alzheimer's Dis. 2005, 7, 125-133.
101. Fu, Y.J.; Xiong, S.; Lovell, M.A.; Lynn, B.C. Quantitative proteomic analysis of mitochondria in aging PS-1 transgenic mice. Cell Mol. Neurobiol. 2009, 29, 649-664.
102. Choe, L.; D'Ascenzo, M.; Relkin, N.R.; Pappin, D.; Ross, P.; Williamson, B.; Guertin, S.; Pribil, P.; Lee, K.H. 8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease. Proteomics 2007, 7, 3651-3660.
103. Beynon, R.J.; Doherty, M.K.; Pratt, J.M.; Gaskell, S.J. Multiplexed absolute quantification in proteomics using artificial QCAT proteins of concatenated signature peptides. Nat. Methods 2005, 2, 587-589.
104. Ding, C.; Li, Y.; Kim, B.J.; Malovannaya, A.; Jung, S.Y.; Wang, Y.; Qin, J. Quantitative analysis of cohesin complex stoichiometry and SMC3 modification-dependent protein interactions. J. Proteome Res. 2011, 10, 3652-3659.
105. Chen, J.; Wang, M.; Turko, I.V. Mass spectrometry quantification of clusterin in the human brain. Mol. Neurodegener. 2012, 7, 41, doi:10.1186/1750-1326-7-41.
106. Chen, J.; Wang, M.; Turko, I.V. Quantification of amyloid precursor protein isoforms using quantification concatamer internal standard. Anal. Chem. 2013, 85, 303-307.
107. Kingsmore, S.F. Multiplexed protein measurement: Technologies and applications of protein and antibody arrays. Nat. Rev. Drug Discov. 2006, 5, 310-320.
108. Vitzthum, F.; Behrens, F.; Anderson, N.L.; Shaw, J.H. Proteomics: From basic research to diagnostic application. A review of requirements & needs. J. Proteome Res. 2005, 4, 1086-1097.
109. Lista, S.; Faltraco, F.; Prvulovic, D.; Hampel, H. Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog. Neurobiol. 2013, 101, 1-17.
110. Wei, X.; Li, L. Mass spectrometry-based proteomics and peptidomics for biomarker discovery in neurodegenerative diseases. Int. J. Clin. Exp. Pathol. 2009, 2, 132-148.
111. Khorvash, F.; Abdi, F.; Dialami, K.; Kooshki, A.M. Can serum procalcitonin and C-reactive protein as nosocomial infection markers in hospitalized patients without localizing signs? J. Res. Med. Sci. 2011, 16, 1280-1285.
112. Abdi, F.; Quinn, J.F.; Jankovic, J.; McIntosh, M.; Leverenz, J.B.; Peskind, E.; Nixon, R.; Nutt, J.; Chung, K.; Zabetian, C., et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimer's Dis. 2006, 9, 293-348.
113. Aebersold, R.; Burlingame, A.L.; Bradshaw, R.A. Western blots versus selected reaction monitoring assays: Time to turn the tables? Mol. Cell Proteomics 2013, 12, 2381-2382.
114. Shi, M.; Caudle, W.M.; Zhang, J., Biomarker discovery in neurodegenerative diseases: A proteomic approach. Neurobiol. Dis. 2009, 35, 157-164.
115. Zhang, K.; Schrag, M.; Crofton, A.; Trivedi, R.; Vinters, H.; Kirsch, W. Targeted proteomics for quantification of histone acetylation in Alzheimer's disease. Proteomics 2012, 12, 1261-1268.
116. Pannee, J.; Portelius, E.; Oppermann, M.; Atkins, A.; Hornshaw, M.; Zegers, I.; Hojrup, P.; Minthon, L.; Hansson, O.; Zetterberg, H., et al. A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. J. Alzheimer's Dis. 2013, 33, 1021-1032.
117. Menschaert, G.; Vandekerckhove, T.T.; Baggerman, G.; Schoofs, L.; Luyten, W.; van Criekinge, W. Peptidomics coming of age: A review of contributions from a bioinformatics angle. J. Proteome Res. 2010, 9, 2051-2061.
118. Tinoco, A.D.; Saghatelian, A. Investigating endogenous peptides and peptidases using peptidomics. Biochemistry 2011, 50, 7447-7461.
119. Monacelli, F.; Borghi, R.; Pacini, D.; Serrati, C.; Traverso, N.; Odetti, P. Pentosidine determination in CSF: A potential biomarker of alzheimer'disease? Clin. Chem. Lab. Med. 2014, 52, 1-4.
120. Kingwell, K. Alzheimer disease: CSF levels of mitochondrial DNA-A new biomarker for preclinical alzheimer disease? Nat. Rev. Neurol. 2013, 9, 420.
121. Ertekin-Taner, N. Alzheimer disease: The quest for Alzheimer disease genes-Focus on CSF tau. Nat. Rev. Neurol. 2013, 9, 368-370.
122. Schmidt, C.; Artjomova, S.; Hoeschel, M.; Zerr, I. CSF prion protein concentration and cognition in patients with Alzheimer disease. Prion 2013, 7, 229-234.
123. Wijte, D.; McDonnell, L.A.; Balog, C.I.; Bossers, K.; Deelder, A.M.; Swaab, D.F.; Verhaagen, J.; Mayboroda, O.A. A novel peptidomics approach to detect markers of Alzheimer's disease in cerebrospinal fluid. Methods 2012, 56, 500-507.
124. Ballatore, C.; Lee, V.M.-Y.; Trojanowski, J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 2007, 8, 663-672.
125. Ando, K.; Dourlen, P.; Sambo, A.V.; Bretteville, A.; Belarbi, K.; Vingtdeux, V.; Eddarkaoui, S.; Drobecq, H.; Ghestem, A.; Begard, S., et al. Tau pathology modulates PIN1 post-translational modifications and may be relevant as biomarker. Neurobiol. Aging 2013, 34, 757-769.
126. Opii, W.O.; Joshi, G.; Head, E.; Milgram, N.W.; Muggenburg, B.A.; Klein, J.B.; Pierce, W.M.; Cotman, C.W.; Butterfield, D.A. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: Relevance to Alzheimer's disease. Neurobiol. Aging 2008, 29, 51-70.
127. Zhang, J. Proteomics of human cerebrospinal fluid-The good, the bad, and the ugly. PROTEOMICS-Clin. Appl. 2007, 1, 805-819.
128. Deja, S.; Barg, E.; Mlynarz, P.; Basiak, A.; Willak-Janc, E. 1H NMR-based metabolomics studies of urine reveal differences between type 1 diabetic patients with high and low HbAc1 values. J Pharm. Biomed. Anal. 2013, 83, 43-48.
129. Huang, Y.; Tian, Y.; Li, G.; Li, Y.; Yin, X.; Peng, C.; Xu, F.; Zhang, Z. Discovery of safety biomarkers for realgar in rat urine using UFLC-IT-TOF/MS and 1H NMR based metabolomics. Anal. Bioanal. Chem. 2013, 405, 4811-4822.
130. Fukuhara, K.; Ohno, A.; Ota, Y.; Senoo, Y.; Maekawa, K.; Okuda, H.; Kurihara, M.; Okuno, A.; Niida, S.; Saito, Y., et al. NMR-based metabolomics of urine in a mouse model of Alzheimer's disease: Identification of oxidative stress biomarkers. J. Clin. Biochem. Nutr. 2013, 52, 133-138.
131. Li, N.J.; Liu, W.T.; Li, W.; Li, S.Q.; Chen, X.H.; Bi, K.S.; He, P. Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. Clin. Biochem. 2010, 43, 992-997.
132. Wishart, D.S.; Knox, C.; Guo, A.C.; Eisner, R.; Young, N.; Gautam, B.; Hau, D.D.; Psychogios, N.; Dong, E.; Bouatra, S., et al. Hmdb: A knowledgebase for the human metabolome. Nucleic Acids Res. 2009, 37, 603-610.
133. Gika, H.G.; Theodoridis, G.A.; Plumb, R.S.; Wilson, I.D. Current practice of liquid chromatography-mass spectrometry in metabolomics and metabonomics. J. Pharm. Biomed. Anal. 2014, 87, 12-25.